Effects of single and multiple doses of a new reversible MAO‐A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects

Abstract

AbstractThe effects on memory, psychomotor performance and mood of two dosage regimens of befloxatone, a new reversible and selective MAO‐A inhibitor were assessed in a randomized, double‐blind, cross‐over, placebo‐controlled study involving 12 healthy young male volunteers. Befloxatone and a placebo were orally administered as single (5 and 10 mg) and repeated doses (10 mg once daily and 5 mg twice daily) at one week wash‐out intervals. Objective tests evaluated both memory (working memory, immediate and delayed free recall of a word list, dual coding and faces recognition) and vigilance continuous performance task (CPT), and digit symbol substitution (DSST). Subjective mood and sleep were assessed using visual analogue scales and the Leeds Sleep Evaluation Questionnaire. Statistical analysis was conducted using an ANOVA with pairwise comparisons using the Student Newman Keuls procedure.Both dosage regimens of befloxatone (10 mg once daily or 5 mg twice daily) were free of any detrimental effect on vigilance (CPT) and information processing (DSST) and did not significantly disrupt short‐ and long‐term memory (working memory, free recall of words, dual coding and faces recognition). In addition, no subjective sedation or sleep disturbances were recorded.In conclusion, this study gives no evidence to suggest that befloxatone, at a daily dose which shows potent MAO‐A inhibition, has any sedative or amnestic properties likely to interfere with the activities of everyday‐life in young subjects and therefore may be safely administered in depressed outpatients.